Published in Hematology Am Soc Hematol Educ Program on January 01, 2002
Platelet adhesive dynamics. Part II: high shear-induced transient aggregation via GPIbalpha-vWF-GPIbalpha bridging. Biophys J (2008) 1.32
Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays. Semin Thromb Hemost (2005) 1.00
A shear-based assay for assessing plasma ADAMTS13 activity and inhibitors in patients with thrombotic thrombocytopenic purpura. Transfusion (2011) 0.82
Upshaw-Schulman Syndrome. Med J Armed Forces India (2011) 0.75
Thrombotic thrombocytopenic purpura - analysis of clinical features, laboratory characteristics and therapeutic outcome of 24 patients treated at a Tertiary Care Center in Saudi Arabia. Pak J Med Sci (2017) 0.75
Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood (2009) 3.18
von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood (2010) 2.82
Elevated nucleosome levels in systemic inflammation and sepsis. Crit Care Med (2003) 2.76
Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med (2003) 2.49
Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13. J Biol Chem (2003) 2.12
Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease. Proc Natl Acad Sci U S A (2006) 2.07
Integrin alpha(v)beta(3) on human endothelial cells binds von Willebrand factor strings under fluid shear stress. Blood (2008) 2.04
Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program (2004) 1.94
Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports. Haematologica (2007) 1.87
Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. Blood (2012) 1.87
Assembly of Weibel-Palade body-like tubules from N-terminal domains of von Willebrand factor. Proc Natl Acad Sci U S A (2008) 1.81
Extensive contacts between ADAMTS13 exosites and von Willebrand factor domain A2 contribute to substrate specificity. Blood (2008) 1.74
Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress. Blood (2007) 1.71
Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol (2008) 1.69
Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood (2004) 1.67
Rapid determination of anti-heparin/platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopenia. Am J Med (2003) 1.64
Binding of ADAMTS13 to von Willebrand factor. J Biol Chem (2005) 1.58
Binding of platelet glycoprotein Ibalpha to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13. Proc Natl Acad Sci U S A (2004) 1.56
Functional architecture of Weibel-Palade bodies. Blood (2011) 1.55
Stability of coagulation assays performed in plasma from citrated whole blood transported at ambient temperature. Thromb Haemost (2008) 1.50
Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura. Blood (2014) 1.47
Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica (2007) 1.39
Cleavage of the ADAMTS13 propeptide is not required for protease activity. J Biol Chem (2003) 1.39
Cleavage of ultralarge multimers of von Willebrand factor by C-terminal-truncated mutants of ADAMTS-13 under flow. Blood (2005) 1.30
Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood (2002) 1.29
ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood (2005) 1.27
Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011. Transfusion (2012) 1.27
Zinc and calcium ions cooperatively modulate ADAMTS13 activity. J Biol Chem (2005) 1.27
Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood (2004) 1.20
Shiga toxin B subunits induce VWF secretion by human endothelial cells and thrombotic microangiopathy in ADAMTS13-deficient mice. Blood (2010) 1.17
Medicine: K is for koagulation. Nature (2004) 1.17
C1-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction. Crit Care Med (2002) 1.14
Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood (2013) 1.13
Two Cys residues essential for von Willebrand factor multimer assembly in the Golgi. Proc Natl Acad Sci U S A (2007) 1.09
Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion (2009) 1.09
A covalent oxidoreductase intermediate in propeptide-dependent von Willebrand factor multimerization. J Biol Chem (2004) 1.08
Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHLBI/NIH guidelines. Am J Hematol (2009) 1.05
Phylogenetic and functional analysis of histidine residues essential for pH-dependent multimerization of von Willebrand factor. J Biol Chem (2011) 1.03
Unfolding the A2 domain of von Willebrand factor with the optical trap. Biophys J (2010) 1.03
A structural explanation for the antithrombotic activity of ARC1172, a DNA aptamer that binds von Willebrand factor domain A1. Structure (2009) 1.03
Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism. J Gen Intern Med (2014) 1.02
Crystal structure of von Willebrand factor A1 domain complexed with snake venom, bitiscetin: insight into glycoprotein Ibalpha binding mechanism induced by snake venom proteins. J Biol Chem (2003) 1.02
Elevated levels of plasma prekallikrein, high molecular weight kininogen and factor XI in coronary heart disease. Atherosclerosis (2002) 0.99
Is factor V Leiden a risk factor for thrombotic microangiopathies without severe ADAMTS 13 deficiency? Thromb Haemost (2005) 0.99
Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura. Haematologica (2011) 0.99
Effect of low-molecular weight dextran sulfate on coagulation and platelet function tests. Thromb Res (2002) 0.98
Rearranging exosites in noncatalytic domains can redirect the substrate specificity of ADAMTS proteases. J Biol Chem (2012) 0.97
Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol (2007) 0.97
ADAMTS13 and TTP. Curr Opin Hematol (2002) 0.95
ADAMTS13 activity in sickle cell disease. Am J Hematol (2006) 0.95
Enteropeptidase, a type II transmembrane serine protease. Front Biosci (Elite Ed) (2009) 0.93
ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13. Br J Haematol (2003) 0.92
Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes. Am J Hematol (2010) 0.92
von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience. Semin Hematol (2004) 0.92
D-dimers predict stroke subtype when assessed early. Cerebrovasc Dis (2009) 0.92
Cognitive deficits after recovery from thrombotic thrombocytopenic purpura. Transfusion (2009) 0.92
Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. Am J Hematol (2012) 0.91
Mucin-like domain of enteropeptidase directs apical targeting in Madin-Darby canine kidney cells. J Biol Chem (2002) 0.91
Should all adult patients with diarrhoea-associated HUS receive plasma exchange? Lancet (2012) 0.91
Frequency and significance of HIV infection among patients diagnosed with thrombotic thrombocytopenic purpura. Clin Infect Dis (2009) 0.91
Thrombin-targeted liposomes establish a sustained localized anticlotting barrier against acute thrombosis. Mol Pharm (2013) 0.90
Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency. Transfusion (2011) 0.90
The Swiss cohort of elderly patients with venous thromboembolism (SWITCO65+): rationale and methodology. J Thromb Thrombolysis (2013) 0.90
Identification of the regulatory elements of the human von Willebrand factor for binding to platelet GPIb. Importance of structural integrity of the regions flanked by the CYS1272-CYS1458 disulfide bond. J Biol Chem (2002) 0.88
Thrombotic microangiopathic syndromes associated with drugs, HIV infection, hematopoietic stem cell transplantation and cancer. Presse Med (2012) 0.88
Mutations in the proenteropeptidase gene are the molecular cause of congenital enteropeptidase deficiency. Am J Hum Genet (2001) 0.87
The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome Registry: the Swiss connection. Eur J Haematol (2008) 0.87
Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease. Haematologica (2008) 0.86
A common origin of the 4143insA ADAMTS13 mutation. Thromb Haemost (2006) 0.86
Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients. Blood (2008) 0.86
Familial acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twins. Blood (2004) 0.86
Shiga toxin (Stx)1B and Stx2B induce von Willebrand factor secretion from human umbilical vein endothelial cells through different signaling pathways. Blood (2011) 0.85
Contact system activation in human sepsis - 47kD HK, a marker of sepsis severity? Swiss Med Wkly (2008) 0.85
Titre of anti-heparin/PF4-antibodies and extent of in vivo activation of the coagulation and fibrinolytic systems. Thromb Haemost (2004) 0.85
A first case of congenital TTP on the African continent due to a new homozygous mutation in the catalytic domain of ADAMTS13. Ann Hematol (2008) 0.85
Characterization of the residues involved in the human alpha-thrombin-haemadin complex: an exosite II-binding inhibitor. Biochemistry (2002) 0.84
Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis. Thromb Haemost (2007) 0.84
A recombinant murine meizothrombin precursor, prothrombin R157A/R268A, inhibits thrombosis in a model of acute carotid artery injury. Blood (2004) 0.84
Sporadic bloody diarrhoea-associated thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome: an adult and paediatric comparison. Br J Haematol (2008) 0.84
Plasma therapy in thrombotic thrombocytopenic purpura: review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiency. Semin Hematol (2004) 0.84
Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura. A case report and concise review of the literature. Swiss Med Wkly (2007) 0.81
Prekallikrein deficiency: the characteristic normalization of the severely prolonged aPTT following increased preincubation time is due to autoactivation of factor XII. Thromb Res (2002) 0.81
Factor XIII in severe sepsis and septic shock. Thromb Res (2006) 0.81
Design and establishment of a biobank in a multicenter prospective cohort study of elderly patients with venous thromboembolism (SWITCO65+). J Thromb Thrombolysis (2013) 0.80
Rapid exclusion or confirmation of heparin-induced thrombocytopenia: a single-center experience with 1,291 patients. Haematologica (2011) 0.80
Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura. Haematologica (2004) 0.80
Factor XI/ADAMTS13 complexes are quantitatively insignificant in human plasma. Haematologica (2007) 0.79
Evaluation of a Platelet Function Analyser (PFA-100) in patients with a bleeding tendency. Swiss Med Wkly (2002) 0.79
Identification of amino acid residues essential for heparin binding by the A1 domain of human von Willebrand factor. Biochem Biophys Res Commun (2005) 0.79
Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program (2012) 0.78
Hemostatic risk factors in ischemic stroke. Thromb Haemost (2003) 0.78
The B subunits of Shiga-like toxins induce regulated VWF secretion in a phospholipase D1-dependent manner. Blood (2012) 0.78
Rumpel-Leede sign in thrombocytopenia due to Epstein-Barr virus-induced mononucleosis. Br J Haematol (2009) 0.77
Massive muscle haematoma three months after starting vitamin K antagonist therapy for deep-vein thrombosis in an antithrombin deficient patient: another case of factor IX propeptide mutation. Thromb Haemost (2011) 0.77
Assays of von Willebrand factor-cleaving protease: a test for diagnosis of familial and acquired thrombotic thrombocytopenic purpura. Semin Thromb Hemost (2002) 0.77
Effective therapy with tranexamic acid in a case of chronic disseminated intravascular coagulation with acquired alpha2-antiplasmin deficiency associated with AL amyloidosis. Thromb Haemost (2009) 0.76
Hemophilia A pseudoaneurysm in a patient with high responding inhibitors complicating total knee arthroplasty: embolization: a cost-reducing alternative to medical therapy. Cardiovasc Intervent Radiol (2006) 0.76